Biocytogen reports stable 446.90 million authorised shares and confirms public-float compliance for June 2026

Bulletin Express07-03

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. released its Monthly Return for Equity Issuer and Hong Kong Depositary Receipts for the period ended 30 June 2026, showing no changes in either authorised or issued share capital across its H-share and A-share tranches.

Authorised/registered share capital remained at 446.90 million shares, split between 110.78 million H shares listed in Hong Kong and 336.12 million A shares traded on the STAR Market of the Shanghai Stock Exchange. Par value for both classes is RMB 1 per share.

Issued share totals were unchanged at 110.78 million H shares and 336.12 million A shares, with the company holding no treasury shares in either class. Consequently, the overall issued share count stood at 446.90 million.

The company confirmed compliance with Hong Kong’s public-float requirement for PRC issuers—set at a minimum 5% of the relevant share class—indicating adequate market liquidity in its H-share segment.

No movements were recorded in relation to share options, warrants, convertible securities or other equity-linked instruments during the month.

The filing was signed by Joint Company Secretary Mr. Wang Yongliang on 3 July 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1114021760?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-03 15:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1114021760","market":"us","top_or_hot":-1,"title":"Biocytogen reports stable 446.90 million authorised shares and confirms public-float compliance for June 2026","media":"Bulletin Express","content":"<p>Biocytogen Pharmaceuticals (Beijing) Co., Ltd. released its Monthly Return for Equity Issuer and Hong Kong Depositary Receipts for the period ended 30 June 2026, showing no changes in either authorised or issued share capital across its H-share and A-share tranches.</p>\n<p>Authorised/registered share capital remained at 446.90 million shares, split between 110.78 million H shares listed in Hong Kong and 336.12 million A shares traded on the STAR Market of the Shanghai Stock Exchange. Par value for both classes is RMB 1 per share.</p>\n<p>Issued share totals were unchanged at 110.78 million H shares and 336.12 million A shares, with the company holding no treasury shares in either class. Consequently, the overall issued share count stood at 446.90 million.</p>\n<p>The company confirmed compliance with Hong Kong’s public-float requirement for PRC issuers—set at a minimum 5% of the relevant share class—indicating adequate market liquidity in its H-share segment.</p>\n<p>No movements were recorded in relation to share options, warrants, convertible securities or other equity-linked instruments during the month.</p>\n<p>The filing was signed by Joint Company Secretary Mr. Wang Yongliang on 3 July 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biocytogen reports stable 446.90 million authorised shares and confirms public-float compliance for June 2026</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiocytogen reports stable 446.90 million authorised shares and confirms public-float compliance for June 2026\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-07-03 15:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Biocytogen Pharmaceuticals (Beijing) Co., Ltd. released its Monthly Return for Equity Issuer and Hong Kong Depositary Receipts for the period ended 30 June 2026, showing no changes in either authorised or issued share capital across its H-share and A-share tranches.</p>\n<p>Authorised/registered share capital remained at 446.90 million shares, split between 110.78 million H shares listed in Hong Kong and 336.12 million A shares traded on the STAR Market of the Shanghai Stock Exchange. Par value for both classes is RMB 1 per share.</p>\n<p>Issued share totals were unchanged at 110.78 million H shares and 336.12 million A shares, with the company holding no treasury shares in either class. Consequently, the overall issued share count stood at 446.90 million.</p>\n<p>The company confirmed compliance with Hong Kong’s public-float requirement for PRC issuers—set at a minimum 5% of the relevant share class—indicating adequate market liquidity in its H-share segment.</p>\n<p>No movements were recorded in relation to share options, warrants, convertible securities or other equity-linked instruments during the month.</p>\n<p>The filing was signed by Joint Company Secretary Mr. Wang Yongliang on 3 July 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02315","symbol_name":"百奥赛图-B","start_time":0,"source_url":"","article_id":"1114021760","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1114021760","pubTimestamp":1783062369,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Biocytogen Pharmaceuticals (Beijing) Co., Ltd. released its Monthly Return for Equity Issuer and Hong Kong Depositary Receipts for the period ended 30 June 2026, showing no changes in either...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02315":"百奥赛图-B"},"translate_title":"百奥赛图报告稳定的44690万股授权股份，并确认2026年6月公众持股量合规性","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02315":1},"content_text":"Biocytogen Pharmaceuticals (Beijing) Co., Ltd. released its Monthly Return for Equity Issuer and Hong Kong Depositary Receipts for the period ended 30 June 2026, showing no changes in either authorised or issued share capital across its H-share and A-share tranches.\nAuthorised/registered share capital remained at 446.90 million shares, split between 110.78 million H shares listed in Hong Kong and 336.12 million A shares traded on the STAR Market of the Shanghai Stock Exchange. Par value for both classes is RMB 1 per share.\nIssued share totals were unchanged at 110.78 million H shares and 336.12 million A shares, with the company holding no treasury shares in either class. Consequently, the overall issued share count stood at 446.90 million.\nThe company confirmed compliance with Hong Kong’s public-float requirement for PRC issuers—set at a minimum 5% of the relevant share class—indicating adequate market liquidity in its H-share segment.\nNo movements were recorded in relation to share options, warrants, convertible securities or other equity-linked instruments during the month.\nThe filing was signed by Joint Company Secretary Mr. Wang Yongliang on 3 July 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1114021760","isCrawlerRequest":true}